Friday, January 4, 2019
Miragen Therapeutics initiated at Baird
Miragen Therapeutics initiated with an Outperform at Baird. Baird analyst Madhu Kumar initiated Miragen Therapeutics with an Outperform rating, citing its near cash valuation, potential for its drug candidate in mycosis fungoides, and its undervalued MicroRNA platform. Kumar has a $10 price target on Miragen Therapeutics shares.
https://thefly.com/landingPageNews.php?id=2843853
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.